This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Pace, J. L.
Right arrow Articles by Kaniga, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Pace, J. L.
Right arrow Articles by Kaniga, K.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, November 2003, p. 3602-3604, Vol. 47, No. 11
0066-4804/03/$08.00+0     DOI: 10.1128/AAC.47.11.3602-3604.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.

In Vitro Activity of TD-6424 against Staphylococcus aureus

John L. Pace, Kevin Krause, Deborah Johnston, Dmitri Debabov, Terry Wu, Lesley Farrington, Cassie Lane, Deborah L. Higgins, Burt Christensen, J. Kevin Judice,{dagger} and Koné Kaniga*

Theravance, Inc., South San Francisco, California 94080

Received 30 May 2003/ Returned for modification 21 July 2003/ Accepted 25 August 2003

TD-6424, a rapidly bactericidal agent with multiple mechanisms of action, is more potent in vitro and more rapidly bactericidal than currently available agents against methicillin-susceptible and methicillin-resistant Staphylococcus aureus. TD-6424 produces a postantibiotic effect with a duration of 4 to 6 h against these organisms. The results suggest potential efficacy against susceptible and resistant strains of S. aureus.

* Corresponding author. Mailing address: Theravance, Inc., 901 Gateway Blvd, South San Francisco, CA 94080. Phone: (650) 808-6158. Fax: (650) 808-6186. E-mail: kkaniga{at}theravance.com.

{dagger} Present address: Department of Medicinal Chemistry, Genentech, Inc., South San Francisco, CA 94080.

Antimicrobial Agents and Chemotherapy, November 2003, p. 3602-3604, Vol. 47, No. 11
0066-4804/03/$08.00+0     DOI: 10.1128/AAC.47.11.3602-3604.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Kosowska-Shick, K., Clark, C., Pankuch, G. A., McGhee, P., Dewasse, B., Beachel, L., Appelbaum, P. C. (2009). Activity of Telavancin against Staphylococci and Enterococci Determined by MIC and Resistance Selection Studies. Antimicrob. Agents Chemother. 53: 4217-4224 [Abstract] [Full Text]  
  • Lunde, C. S., Hartouni, S. R., Janc, J. W., Mammen, M., Humphrey, P. P., Benton, B. M. (2009). Telavancin Disrupts the Functional Integrity of the Bacterial Membrane through Targeted Interaction with the Cell Wall Precursor Lipid II. Antimicrob. Agents Chemother. 53: 3375-3383 [Abstract] [Full Text]  
  • Charneski, L., Patel, P. N, Sym, D. (2009). Telavancin: A Novel Lipoglycopeptide Antibiotic. The Annals of Pharmacotherapy 43: 928-938 [Abstract] [Full Text]  
  • Hegde, S. S., Difuntorum, S., Skinner, R., Trumbull, J., Krause, K. M. (2009). Efficacy of telavancin against glycopeptide-intermediate Staphylococcus aureus in the neutropenic mouse bacteraemia model. J Antimicrob Chemother 63: 763-766 [Abstract] [Full Text]  
  • Pankuch, G. A., Appelbaum, P. C. (2009). Postantibiotic Effects of Telavancin against 16 Gram-Positive Organisms. Antimicrob. Agents Chemother. 53: 1275-1277 [Abstract] [Full Text]  
  • Lubenko, I. Yu., Strukova, E. V., Smirnova, M. V., Vostrov, S. N., Portnoy, Y. A., Zinner, S. H., Firsov, A. A. (2008). Telavancin and vancomycin pharmacodynamics with Staphylococcus aureus in an in vitro dynamic model. J Antimicrob Chemother 62: 1065-1069 [Abstract] [Full Text]  
  • Wong, S. L., Barriere, S. L., Kitt, M. M., Goldberg, M. R. (2008). Multiple-dose pharmacokinetics of intravenous telavancin in healthy male and female subjects. J Antimicrob Chemother 62: 780-783 [Abstract] [Full Text]  
  • Draghi, D. C., Benton, B. M., Krause, K. M., Thornsberry, C., Pillar, C., Sahm, D. F. (2008). In vitro activity of telavancin against recent Gram-positive clinical isolates: results of the 2004-05 Prospective European Surveillance Initiative. J Antimicrob Chemother 62: 116-121 [Abstract] [Full Text]  
  • Krause, K. M., Renelli, M., Difuntorum, S., Wu, T. X., Debabov, D. V., Benton, B. M. (2008). In Vitro Activity of Telavancin against Resistant Gram-Positive Bacteria. Antimicrob. Agents Chemother. 52: 2647-2652 [Abstract] [Full Text]  
  • Draghi, D. C., Benton, B. M., Krause, K. M., Thornsberry, C., Pillar, C., Sahm, D. F. (2008). Comparative Surveillance Study of Telavancin Activity against Recently Collected Gram-Positive Clinical Isolates from across the United States. Antimicrob. Agents Chemother. 52: 2383-2388 [Abstract] [Full Text]  
  • Barcia-Macay, M., Mouaden, F., Mingeot-Leclercq, M.-P., Tulkens, P. M., Van Bambeke, F. (2008). Cellular pharmacokinetics of telavancin, a novel lipoglycopeptide antibiotic, and analysis of lysosomal changes in cultured eukaryotic cells (J774 mouse macrophages and rat embryonic fibroblasts). J Antimicrob Chemother 61: 1288-1294 [Abstract] [Full Text]  
  • Hegde, S. S., Reyes, N., Skinner, R., Difuntorum, S. (2008). Efficacy of telavancin in a murine model of pneumonia induced by methicillin-susceptible Staphylococcus aureus. J Antimicrob Chemother 61: 169-172 [Abstract] [Full Text]  
  • Attwood, R. J., LaPlante, K. L. (2007). Telavancin: A novel lipoglycopeptide antimicrobial agent. Am J Health Syst Pharm 64: 2335-2348 [Abstract] [Full Text]  
  • Jansen, W. T. M., Verel, A., Verhoef, J., Milatovic, D. (2007). In Vitro Activity of Telavancin against Gram-Positive Clinical Isolates Recently Obtained in Europe. Antimicrob. Agents Chemother. 51: 3420-3424 [Abstract] [Full Text]  
  • Odenholt, I., Lowdin, E., Cars, O. (2007). Pharmacodynamic Effects of Telavancin against Methicillin-Resistant and Methicillin-Susceptible Staphylococcus aureus Strains in the Presence of Human Albumin or Serum and in an In Vitro Kinetic Model. Antimicrob. Agents Chemother. 51: 3311-3316 [Abstract] [Full Text]  
  • Miro, J. M., Garcia-de-la-Maria, C., Armero, Y., de-Lazzari, E., Soy, D., Moreno, A., del Rio, A., Almela, M., Mestres, C. A., Gatell, J. M., Jimenez-de-Anta, M.-T., Marco, F., and the Hospital Clinic Experimental Endocarditis, (2007). Efficacy of Telavancin in the Treatment of Experimental Endocarditis Due to Glycopeptide-Intermediate Staphylococcus aureus. Antimicrob. Agents Chemother. 51: 2373-2377 [Abstract] [Full Text]  
  • Reyes, N., Skinner, R., Benton, B. M., Krause, K. M., Shelton, J., Obedencio, G. P., Hegde, S. S. (2006). Efficacy of telavancin in a murine model of bacteraemia induced by methicillin-resistant Staphylococcus aureus. J Antimicrob Chemother 58: 462-465 [Abstract] [Full Text]  
  • Leuthner, K. D., Cheung, C. M., Rybak, M. J. (2006). Comparative activity of the new lipoglycopeptide telavancin in the presence and absence of serum against 50 glycopeptide non-susceptible staphylococci and three vancomycin-resistant Staphylococcus aureus. J Antimicrob Chemother 58: 338-343 [Abstract] [Full Text]  
  • Stryjewski, M. E., Chu, V. H., O'Riordan, W. D., Warren, B. L., Dunbar, L. M., Young, D. M., Vallee, M., Fowler, V. G. Jr., Morganroth, J., Barriere, S. L., Kitt, M. M., Corey, G. R., for the FAST 2 Investigator Group, (2006). Telavancin versus Standard Therapy for Treatment of Complicated Skin and Skin Structure Infections Caused by Gram-Positive Bacteria: FAST 2 Study. Antimicrob. Agents Chemother. 50: 862-867 [Abstract] [Full Text]  
  • Sun, H. K., Duchin, K., Nightingale, C. H., Shaw, J.-P., Seroogy, J., Nicolau, D. P. (2006). Tissue Penetration of Telavancin after Intravenous Administration in Healthy Subjects. Antimicrob. Agents Chemother. 50: 788-790 [Abstract] [Full Text]  
  • Reyes, N., Skinner, R., Kaniga, K., Krause, K. M., Shelton, J., Obedencio, G. P., Gough, A., Conner, M., Hegde, S. S. (2005). Efficacy of Telavancin (TD-6424), a Rapidly Bactericidal Lipoglycopeptide with Multiple Mechanisms of Action, in a Murine Model of Pneumonia Induced by Methicillin-Resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 49: 4344-4346 [Abstract] [Full Text]  
  • Madrigal, A. G., Basuino, L., Chambers, H. F. (2005). Efficacy of Telavancin in a Rabbit Model of Aortic Valve Endocarditis Due to Methicillin-Resistant Staphylococcus aureus or Vancomycin-Intermediate Staphylococcus aureus. Antimicrob. Agents Chemother. 49: 3163-3165 [Abstract] [Full Text]  
  • Higgins, D. L., Chang, R., Debabov, D. V., Leung, J., Wu, T., Krause, K. M., Sandvik, E., Hubbard, J. M., Kaniga, K., Schmidt, D. E. Jr., Gao, Q., Cass, R. T., Karr, D. E., Benton, B. M., Humphrey, P. P. (2005). Telavancin, a Multifunctional Lipoglycopeptide, Disrupts both Cell Wall Synthesis and Cell Membrane Integrity in Methicillin-Resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 49: 1127-1134 [Abstract] [Full Text]  
  • Shaw, J. P., Seroogy, J., Kaniga, K., Higgins, D. L., Kitt, M., Barriere, S. (2005). Pharmacokinetics, Serum Inhibitory and Bactericidal Activity, and Safety of Telavancin in Healthy Subjects. Antimicrob. Agents Chemother. 49: 195-201 [Abstract] [Full Text]  
  • Hegde, S. S., Reyes, N., Wiens, T., Vanasse, N., Skinner, R., McCullough, J., Kaniga, K., Pace, J., Thomas, R., Shaw, J.-P., Obedencio, G., Judice, J. K. (2004). Pharmacodynamics of Telavancin (TD-6424), a Novel Bactericidal Agent, against Gram-Positive Bacteria. Antimicrob. Agents Chemother. 48: 3043-3050 [Abstract] [Full Text]  
  • Stubbings, W. J., Bostock, J. M., Ingham, E., Chopra, I. (2004). Assessment of a microplate method for determining the post-antibiotic effect in Staphylococcus aureus and Escherichia coli. J Antimicrob Chemother 54: 139-143 [Abstract] [Full Text]  
  • Goldstein, E. J. C., Citron, D. M., Merriam, C. V., Warren, Y. A., Tyrrell, K. L., Fernandez, H. T. (2004). In Vitro Activities of the New Semisynthetic Glycopeptide Telavancin (TD-6424), Vancomycin, Daptomycin, Linezolid, and Four Comparator Agents against Anaerobic Gram-Positive Species and Corynebacterium spp.. Antimicrob. Agents Chemother. 48: 2149-2152 [Abstract] [Full Text]  
  • King, A., Phillips, I., Kaniga, K. (2004). Comparative in vitro activity of telavancin (TD-6424), a rapidly bactericidal, concentration-dependent anti-infective with multiple mechanisms of action against Gram-positive bacteria. J Antimicrob Chemother 53: 797-803 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»